Thermal Extraction Devices

Loading search index…

    Thermal engineering & extraction device archive

    Cannabigerol (CBG)

    Identity

    Property Value
    Preferred name Cannabigerol (CBG)
    IUPAC name 2-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-5-pentylbenzene-1,3-diol
    CAS number 25654-31-3 (primary); 2808-33-5 also appears for the same material [^1]
    PubChem CID 5315659
    InChIKey QXACEHWTBCFNSA-SFQUDFHCSA-N [^1]
    Molecular formula C21H32O2
    Molecular mass 316.48 g/mol (exact 316.2402 Da)
    Compound class Phytocannabinoid; resorcinol; meroterpenoid
    Stereochemistry No chiral centers. The (2E) geometry of the geranyl chain is the natural configuration; (2Z)-CBG is non-natural [^1]
    Major synonyms Cannabigerol, CBG, geranylolivetol; decarboxylation product of CBGA

    Identity notes

    • Two CAS numbers (25654-31-3 primary; 2808-33-5) appear for the same material in vendor databases [^1].
    • “Cannabigerol-type” is a compound family in PubChem (16+ derivatives including CBGA, CBGV, quinones); the parent CBG must be distinguished from its derivatives [^1].

    Physical properties

    Property Value Conditions / Notes
    Melting point ≈52 °C (reported) [^2]
    Boiling point No compound-specific atmospheric boiling point was located. The reported 52 °C value is a melting point, not an atmospheric boiling point; a compound-specific reduced-pressure boiling value was also not verified [^2][^3][^5]
    Vapor pressure No direct experimental data or defensible compound-specific estimate was located; THC/CBD measurements must not be presented as CBG vapor pressure [^4]
    logP (octanol-water) 7.4 (computed XLogP3) Extremely lipophilic
    Water solubility Practically insoluble Soluble in ethanol, methanol, acetonitrile, chloroform, scCO₂
    Thermal decomposition In GC-injector tests, CBG decreased by about 35.6% at 250 °C and about 50% at 300 °C, with CBC observed; these injector conditions do not define a universal sample-temperature onset [^3]
    Oxidation / light sensitivity High Store cold, dark, inert

    | Known degradation products | CBC was observed under cited GC-injector conditions [^3]; VCE-003-type quinones remain an unresolved analogy |

    Boiling point is not a device setpoint. “CBG boils at 52 °C” is not a verified atmospheric or reduced-pressure boiling datum; 52 °C is the reported melting point. Vaporizer chamber temperature, device setpoint, and sample temperature are separate from the unresolved thermodynamic boiling point [^2][^3][^5].

    Thermal-extraction context

    CBG release from plant matrix is expected to be vapor-pressure-driven evaporation rather than bulk boiling, but no CBG-specific device/sample-temperature curve was located. The thermodynamic boiling point of the pure compound is not a device setpoint or a sample temperature [^3][^5].

    Cannabis occurrence

    CBG is typically a minor constituent in mature flower (acid form CBGA dominant in fresh material) and is elevated in early-flowering or Type IV (CBG-dominant) material. Values are batch- and report-attached; no universal cultivar claim is made. Consult Lab Results for batch-level measurements.

    Biosynthesis and processing

    CBGA is the shared precursor of the major cannabinoid acids (THCA, CBDA, CBCA) and decarboxylates to CBG. Because CBGA is consumed by the competing synthases, CBG levels are usually low in mature drug-type flower [^2].

    Reported biological activity

    Human evidence

    No controlled human study of inhaled isolated CBG was identified in this archive’s literature review (as of 2026-08-08).

    Preclinical animal and in vitro evidence

    Preclinical studies report CBG modulation of cannabinoid receptors and α2-adrenoceptors, antimicrobial activity, and anti-inflammatory effects in vitro (peer-reviewed review: Jastrząb et al. 2022 1); concentrations exceed plausible human exposure from cannabis.

    Industry claims

    “CBG is the mother of all cannabinoids” is a marketing framing of the precursor role of CBGA (not CBG itself); analgesic/anti-inflammatory marketing claims lack controlled human evidence.

    Degradation products

    • Thermal: CBC (cyclization) under cited GC-injector conditions 2
    • Oxidative: secondary products unresolved; VCE-003-type quinones are an analogy, not a verified CBG result

    Sources

    1. Jastrząb A, Jarocka-Karpowicz I, Skrzydlewska E. The origin and biomedical relevance of cannabigerol. Int J Mol Sci. 2022;23(14):7929. doi:10.3390/ijms23147929. (Peer-reviewed review; CBG identity, properties, and reported biological activities.) ↩

    2. García-Valverde MT, Sánchez-Carnerero Callado C, Díaz-Liñán MC, et al. Effect of temperature in the degradation of cannabinoids: from a brief residence in the gas chromatography inlet port to a longer period in thermal treatments. Front Chem. 2022;10:1038729. doi:10.3389/fchem.2022.1038729. (Thermal degradation of cannabinoids with temperature; CBC emergence from CBG.) ↩

    Derived navigation generated from structured relationships. Links are labeled by edge class and evidence trace; derived links are navigation, not primary assertions.

    Laboratory reports measuring this compound (1)

    Products with measurements (1)

    Related (3)